Total raised
$25.0M
Last: Undisclosed 2013-07
Stage
Series B
Founded
2007
Headcount
12
HQ
Caesarea
Sector
Health Tech & Life Sciences
About
Enopace Biomedical is developing a device to treat patients with heart failure. The company's technology comprises a minimally invasive, implantable neurostimulation device designed to increase cardiac efficiency by reducing left-ventricular workload.
The company's Harmony™ System was designed for heart failure patients and is a minimally invasive neuromodulation implant supplies precise and personalized aortic stimulation, while the wearable unit allows the user to switch the therapy on or off, as needed. The Harmony System can be implanted in 30 minutes in a standard catheterization procedure, without the need for general anesthesia.
Funding history · 3 rounds · $25.0M total
2013-07
Undisclosed
$5.0M
2013-02
Series B
$13.0M
2011-10
Series A
$7.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Enopace Biomedical's technology?
- Enopace Biomedical is developing a minimally invasive, implantable neurostimulation device, called the Harmony™ System, to treat patients with heart failure by increasing cardiac efficiency.
- When was Enopace Biomedical founded?
- Enopace Biomedical was founded in October 2007.
- What is the current operational status of Enopace Biomedical?
- Enopace Biomedical is currently inactive, having ceased operations in February 2025.
- How much total funding has Enopace Biomedical raised?
- Enopace Biomedical has raised a total of $25,000,000 across multiple funding rounds. For a full financing history, please refer to startupim.
- Which investor participated in Enopace Biomedical's Series A funding round?
- Sorin was an investor in Enopace Biomedical's Series A funding round in October 2011.
- When did Enopace Biomedical raise its Series B funding round?
- Enopace Biomedical raised a Series B funding round in February 2013, with Sorin as an investor.
- What was a significant product development announcement for Enopace Biomedical in November 2015?
- In November 2015, Enopace Biomedical announced the world's first endovascular neuromodulation device was implanted in a human for the treatment of congestive heart failure.
- How many employees does Enopace Biomedical currently have?
- Enopace Biomedical has 12 employees.
- Who is a founder of Enopace Biomedical?
- Yossi Gross is a founder of Enopace Biomedical.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
CommunicationsRadio FrequencyWirelessMaterials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
remote-monitoringrf-technologyminimally-invasiveheart-failureneuro-stimulationmedical-devicesclinicsdoctorssensorshealthcare-providerscardiologyhospitalstreatments